Verve Therapeutics set for best day ever on Lilly's up to $1.3 billion deal

Verve Therapeutics

17/06/2025 16:33

Updates

** Shares of genetic medicines developer Verve Therapeutics VERV.O jump as much as 76.5% to more than a one-year high of $11.07

** VERV set for its best day ever, if gains hold

** Eli Lilly LLY.N to buy VERV for up to $1.3 billion

** Deal is expected to close in Q3

** LLY shares slip 1.2% to $797.58

** Cautious on potential acquisition of Verve by Lilly, as "we question the ultimate commercial viability of gene editing for primary care conditions", BMO Capital Markets says

** "While the proposed deal size is low relative to Lilly's investment firepower, we think there may be better uses of capital for the company at this time" - brokerage

** VERV shares up 96% YTD

(Reporting by Joel Jose, Sriparna Roy and Puyaan Singh in Bengaluru)

((joeljose@thomsonreuters.com;))